These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10049300)

  • 1. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
    Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
    Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
    Schick DG; Canawati HN; Montgomerie JZ
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
    Shonekan D; Handwerger S; Mildvan D
    J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Houlihan HH; Rybak MJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
    Zinner SH; Gilbert D; Dudley MN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
    Chambers HF; Kartalija M; Sande M
    J Infect Dis; 1995 Apr; 171(4):897-902. PubMed ID: 7706817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method.
    Thamlikitkul V
    J Med Assoc Thai; 1991 Dec; 74(12):669-74. PubMed ID: 1839906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.
    Palmer SM; Rybak MJ
    J Antimicrob Chemother; 1997 Apr; 39(4):515-8. PubMed ID: 9145825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
    Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
    J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
    McGrath BJ; Kang SL; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2034-40. PubMed ID: 7811015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Cohen MA; Huband MD
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
    Fitoussi F; Doit C; Geslin P; Bingen E
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2372-5. PubMed ID: 10508009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.